Crinetics Pharmaceuticals Inc News - CRNX | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Crinetics Pharmaceuticals Inc (CRNX)
Crinetics Pharmaceuticals Inc (CRNX) News

Crinetics Pharmaceuticals Inc (CRNX)

58.78

-1.23

(-2.05%)

At close: November 12 3:00PM

Delayed by 15 minutes

58.78

0.00

( 0.00% )

After Hours: 3:25PM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate...

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public...

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced...

Form 8-K - Current report

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

1
Next

FALCON1

FALCON1 4 months ago

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri

https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

Monksdream

Monksdream 4 months ago

CRNX new 52 week high

Monksdream

Monksdream 8 months ago

CRNX new 52 week high

Monksdream

Monksdream 1 year ago

CRNX No 1 on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Crinetics Pharmaceuticals

Inv Us Real Est

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions